Company intelligence / Profile preview
Egle Therapeutics
Paris, Franceegle-tx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Egle Therapeutics has advanced its lead immuno-oncology candidate, EGL‑001—a CTLA‑4/CD25 antagonist fusion protein—into a Phase I/II clinical trial for cancer. Its autoimmune disease program, EGL‑003, has completed IND-enabling studies and will enter Phase I trials in early/mid–2025. The company leverages a proprietary platform to discover and develop therapies that modulate regulatory T cells for both oncology and autoimmunity. Recent funding from France’s “France 2030” initiative supports ongoing clinical development[1][2][5].
- Therapeutic areas
- OncologyImmunology
- Modalities
- ImmunotherapiesAntibody-cytokine fusion proteins (e.g., antagonist IL‑2 mutein fused to CTLA‑4 antibody)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals—three-year strategic research collaboration with option agreement since June 2020[2][5].
Beyond the preview
Go deeper on Egle Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Egle Therapeutics.